AAAAAA

   
Results: 1-12 |
Results: 12
Uridine phosphorylase association with vimentin - Intracellular distribution and localization
Authors: Russell, RL Cao, DL Zhang, DK Handschumacher, RE Pizzorno, G
Citation: Rl. Russell et al., Uridine phosphorylase association with vimentin - Intracellular distribution and localization, J BIOL CHEM, 276(16), 2001, pp. 13302-13307
P53-dependent suppression of uridine phosphorylase gene expression throughdirect promoter interaction
Authors: Zhang, DK Cao, DL Russell, R Pizzorno, G
Citation: Dk. Zhang et al., P53-dependent suppression of uridine phosphorylase gene expression throughdirect promoter interaction, CANCER RES, 61(18), 2001, pp. 6899-6905
The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines
Authors: Peng, XY Won, JH Rutherford, T Fujii, T Zelterman, D Pizzorno, G Sapi, E Leavitt, J Kacinski, B Crystal, R Schwartz, P Deisseroth, A
Citation: Xy. Peng et al., The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines, CANCER RES, 61(11), 2001, pp. 4405-4413
A phase I study of the antimetabolite (E)-2 '-fluoromethylene-2 '-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion
Authors: Burtness, B Belker, M Stoltz, M Peccerillo, KM Lamb, LA Chmael, SE McKeon, A Clark, MB Winship, J Marsh, JC Pizzorno, G DeVita, VT
Citation: B. Burtness et al., A phase I study of the antimetabolite (E)-2 '-fluoromethylene-2 '-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion, CANCER J, 6(5), 2000, pp. 309-315
Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer
Authors: Murren, JR Peccerillo, K DiStasio, SA Li, X Leffert, JJ Pizzorno, G Burtness, BA McKeon, A Cheng, YC
Citation: Jr. Murren et al., Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer, CANC CHEMOT, 46(1), 2000, pp. 43-50
A clinical-pharmacological evaluation of percutaneous isolated hepatic infusion of doxorubicin in patients with unresectable liver tumors
Authors: Hwu, WJ Salem, RR Pollak, J Rosenblatt, M D'Andrea, E Leffert, JJ Faraone, S Marsh, JC Pizzorno, G
Citation: Wj. Hwu et al., A clinical-pharmacological evaluation of percutaneous isolated hepatic infusion of doxorubicin in patients with unresectable liver tumors, ONCOL RES, 11(11-12), 1999, pp. 529-537
Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells
Authors: Chung, I Schwartz, PE Crystal, RG Pizzorno, G Leavitt, J Deisseroth, AB
Citation: I. Chung et al., Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells, CANC GENE T, 6(2), 1999, pp. 99-106
beta-alanine and alpha-fluoro-beta-alanine concentrative transport in rat hepatocytes is mediated by GABA transporter GAT-2
Authors: Liu, MP Russell, RL Beigelman, L Handschumacher, RE Pizzorno, G
Citation: Mp. Liu et al., beta-alanine and alpha-fluoro-beta-alanine concentrative transport in rat hepatocytes is mediated by GABA transporter GAT-2, AM J P-GAST, 39(1), 1999, pp. G206-G210
Genomic structure, chromosomal mapping, and promoter region analysis of murine uridine phosphorylase gene
Authors: Cao, DL Nimmakayalu, MA Wang, FY Zhang, DK Handschumacher, RE Bray-Ward, P Pizzorno, G
Citation: Dl. Cao et al., Genomic structure, chromosomal mapping, and promoter region analysis of murine uridine phosphorylase gene, CANCER RES, 59(19), 1999, pp. 4997-5001
In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by F-19 nuclear magnetic resonance spectroscopy
Authors: Adams, ER Leffert, JJ Craig, DJ Spector, T Pizzorno, G
Citation: Er. Adams et al., In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by F-19 nuclear magnetic resonance spectroscopy, CANCER RES, 59(1), 1999, pp. 122-127
Genetic therapy of solid tumor and hematopoietic neoplasms
Authors: Nanakorn, T Fu, SQ Yin, LH Rahman, Z Kavanagh, J Fugii, T Chung, IJ Yap, R Giles, R Pizzorno, G Deisseroth, A
Citation: T. Nanakorn et al., Genetic therapy of solid tumor and hematopoietic neoplasms, PROG ANTI C, 2, 1999, pp. 96-105
Expression, characterization, and detection of human uridine phosphorylaseand identification of variant uridine phosphorolytic activity in selected human tumors
Authors: Liu, MP Cao, DL Russel, R Handschumacher, RE Pizzorno, G
Citation: Mp. Liu et al., Expression, characterization, and detection of human uridine phosphorylaseand identification of variant uridine phosphorolytic activity in selected human tumors, CANCER RES, 58(23), 1998, pp. 5418-5424
Risultati: 1-12 |